{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T18:29:29Z","timestamp":1757615369012,"version":"3.44.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,5]]},"DOI":"10.7759\/cureus.91665","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T13:52:58Z","timestamp":1757080378000},"source":"Crossref","is-referenced-by-count":0,"title":["The Role of Phosphodiesterase-5 Enzyme Inhibitors and Prostacyclin Analogs in Reactive Pulmonary Vasculopathy in Systolic Heart Failure: A Narrative Review"],"prefix":"10.7759","author":[{"given":"Hadassa Evangeline","family":"Sekharamahanti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhruvil Vinaybhai","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manthan","family":"Prajapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vaishnavi","family":"Sirekulam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyank","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamna Talha","family":"Peracha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smitkumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthik Sai","family":"Makineni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer  I","family":"Anene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachana","family":"Harish","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna M","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108815","article-title":"Heart failure subtypes: pathophysiology and definitions","volume":"175","author":"Swedberg K","year":"2021","unstructured":"Swedberg K. Heart failure subtypes: pathophysiology and definitions. Diabetes Res Clin Pract. 2021, 175:108815. 10.1016\/j.diabres.2021.108815","journal-title":"Diabetes Res Clin Pract"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21037\/cdt-20-302","article-title":"Pathophysiology of heart failure","volume":"11","author":"Schwinger RH","year":"2021","unstructured":"Schwinger RH. Pathophysiology of heart failure. Cardiovasc Diagn Ther. 2021, 11:263-76. 10.21037\/cdt-20-302","journal-title":"Cardiovasc Diagn Ther"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0059-2015","article-title":"Under pressure: pulmonary hypertension associated with left heart disease","volume":"24","author":"Farber HW","year":"2015","unstructured":"Farber HW, Gibbs S. Under pressure: pulmonary hypertension associated with left heart disease. Eur Respir Rev. 2015, 24:665-73. 10.1183\/16000617.0059-2015","journal-title":"Eur Respir Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.112.000095","article-title":"Left ventricular dysfunction with pulmonary hypertension: part 1: epidemiology, pathophysiology, and definitions","volume":"6","author":"Georgiopoulou VV","year":"2013","unstructured":"Georgiopoulou VV, Kalogeropoulos AP, Borlaug BA, Gheorghiade M, Butler J. Left ventricular dysfunction with pulmonary hypertension: part 1: epidemiology, pathophysiology, and definitions. Circ Heart Fail. 2013, 6:344-54. 10.1161\/CIRCHEARTFAILURE.112.000095","journal-title":"Circ Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.110.960864","article-title":"Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure","volume":"4","author":"Aronson D","year":"2011","unstructured":"Aronson D, Eitan A, Dragu R, Burger AJ. Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure. Circ Heart Fail. 2011, 4:644-50. 10.1161\/CIRCHEARTFAILURE.110.960864","journal-title":"Circ Heart Fail"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/1753944713477518","article-title":"Management of pulmonary hypertension in left heart disease","volume":"7","author":"Schmeisser A","year":"2013","unstructured":"Schmeisser A, Schroetter H, Braun-Dulleaus RC. Management of pulmonary hypertension in left heart disease. Ther Adv Cardiovasc Dis. 2013, 7:131-51. 10.1177\/1753944713477518","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00124007","article-title":"Phosphodiesterase inhibitors for the treatment of pulmonary hypertension","volume":"32","author":"Wilkins MR","year":"2008","unstructured":"Wilkins MR, Wharton J, Grimminger F, Ghofrani HA. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J. 2008, 32:198-209. 10.1183\/09031936.00124007","journal-title":"Eur Respir J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.112.969071","article-title":"Heart Failure Clinical Research Network. phosphdiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial: rationale and design","volume":"5(5)","author":"Redfield MM","year":"2012","unstructured":"Redfield MM, Borlaug BA, Lewis GD, et al..  Heart Failure Clinical Research Network. phosphdiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure (RELAX) trial: rationale and design. Circ Heart Fail. 2012, 5(5):653-9. 10.1161\/CIRCHEARTFAILURE.112.969071","journal-title":"Circ Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1177\/2045894020948780","article-title":"Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review","volume":"10","author":"Sanchez Palacios GM","year":"2020","unstructured":"Sanchez Palacios GM, Schmidt C, Wichman T. Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review. Pulm Circ. 2020, 10:2045894020948780. 10.1177\/2045894020948780","journal-title":"Pulm Circ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59122190","article-title":"Exploring the multifaceted potential of sildenafil in medicine","volume":"59","author":"Pu\u0219ca\u0219u C","year":"2023","unstructured":"Pu\u0219ca\u0219u C, Zanfirescu A, Negre\u0219 S, \u0218eremet OC. Exploring the multifaceted potential of sildenafil in medicine. Medicina (Kaunas). 2023, 59:2190. 10.3390\/medicina59122190","journal-title":"Medicina (Kaunas)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2174\/0929867327666200923151924","article-title":"Repurposing of the PDE5 inhibitor sildenafil for the treatment of persistent pulmonary hypertension in neonates","volume":"28","author":"Poitras EL","year":"2021","unstructured":"Poitras EL, Gust SL, Kerr PM, Plane F. Repurposing of the PDE5 inhibitor sildenafil for the treatment of persistent pulmonary hypertension in neonates. Curr Med Chem. 2021, 28:2418-37. 10.2174\/0929867327666200923151924","journal-title":"Curr Med Chem"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195528","article-title":"Sildenafil ameliorates right ventricular early molecular derangement during left ventricular pressure overload","volume":"13","author":"Imai Y","year":"2018","unstructured":"Imai Y, Kariya T, Iwakiri M, Yamada Y, Takimoto E. Sildenafil ameliorates right ventricular early molecular derangement during left ventricular pressure overload. PLoS One. 2018, 13:e0195528. 10.1371\/journal.pone.0195528","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-022-10239-5","article-title":"Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure","volume":"27","author":"Triposkiadis F","year":"2022","unstructured":"Triposkiadis F, Xanthopoulos A, Skoularigis J, Starling RC. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure. Heart Fail Rev. 2022, 27:1991-2003. 10.1007\/s10741-022-10239-5","journal-title":"Heart Fail Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-040122-034745","article-title":"Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders","volume":"63","author":"Samidurai A","year":"2023","unstructured":"Samidurai A, Xi L, Das A, Kukreja RC. Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders. Annu Rev Pharmacol Toxicol. 2023, 63:585-615. 10.1146\/annurev-pharmtox-040122-034745","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/17476348.2017.1317599","article-title":"The prostacyclin pathway in pulmonary arterial hypertension: a clinical review","volume":"11","author":"Del Pozo R","year":"2017","unstructured":"Del Pozo R, Hernandez Gonzalez I, Escribano-Subias P. The prostacyclin pathway in pulmonary arterial hypertension: a clinical review. Expert Rev Respir Med. 2017, 11:491-503. 10.1080\/17476348.2017.1317599","journal-title":"Expert Rev Respir Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-023-02559-3","article-title":"Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension","volume":"24","author":"Zeng C","year":"2023","unstructured":"Zeng C, Liu J, Zheng X, Hu X, He Y. Prostaglandin and prostaglandin receptors: present and future promising therapeutic targets for pulmonary arterial hypertension. Respir Res. 2023, 24:263. 10.1186\/s12931-023-02559-3","journal-title":"Respir Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/CE.S50607","article-title":"Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review","volume":"9","author":"Buckley MS","year":"2014","unstructured":"Buckley MS, Berry AJ, Kazem NH, Patel SA, Librodo PA. Clinical utility of treprostinil in the treatment of pulmonary arterial hypertension: an evidence-based review. Core Evid. 2014, 9:71-80. 10.2147\/CE.S50607","journal-title":"Core Evid"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00188013","article-title":"Iloprost reverses established fibrosis in experimental right ventricular failure","volume":"45","author":"Gomez-Arroyo J","year":"2015","unstructured":"Gomez-Arroyo J, Sakagami M, Syed AA, et al.. Iloprost reverses established fibrosis in experimental right ventricular failure. Eur Respir J. 2015, 45:449-62. 10.1183\/09031936.00188013","journal-title":"Eur Respir J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1177\/1535370213498981","article-title":"Synergistic effects of prostacyclin analogs and phosphodiesterase inhibitors on cyclic adenosine 3',5' monophosphate accumulation and adenosine 3'5' triphosphate release from human erythrocytes","volume":"238","author":"Knebel SM","year":"2013","unstructured":"Knebel SM, Elrick MM, Bowles EA, Zdanovec AK, Stephenson AH, Ellsworth ML, Sprague RS. Synergistic effects of prostacyclin analogs and phosphodiesterase inhibitors on cyclic adenosine 3',5' monophosphate accumulation and adenosine 3'5' triphosphate release from human erythrocytes. Exp Biol Med (Maywood). 2013, 238:1069-74. 10.1177\/1535370213498981","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2019.8142","article-title":"A meta-analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension","volume":"18","author":"Dang ZC","year":"2019","unstructured":"Dang ZC, Tang B, Li B, Liu S, Ge RL, Li ZQ, Lu DX. A meta-analysis of the safety and efficacy of bosentan therapy combined with prostacyclin analogues or phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension. Exp Ther Med. 2019, 18:4740-6. 10.3892\/etm.2019.8142","journal-title":"Exp Ther Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1177\/1535370214547155","article-title":"Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension","volume":"240","author":"Bowles EA","year":"2015","unstructured":"Bowles EA, Moody GN, Yeragunta Y, Stephenson AH, Ellsworth ML, Sprague RS. Phosphodiesterase 5 inhibitors augment UT-15C-stimulated ATP release from erythrocytes of humans with pulmonary arterial hypertension. Exp Biol Med (Maywood). 2015, 240:121-7. 10.1177\/1535370214547155","journal-title":"Exp Biol Med (Maywood)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.12659\/msm.881763","article-title":"Identification of cytosolic phosphodiesterases in the erythrocyte: a possible role for PDE5","volume":"17","author":"Adderley SP","year":"2011","unstructured":"Adderley SP, Thuet KM, Sridharan M, Bowles EA, Stephenson AH, Ellsworth ML, Sprague RS. Identification of cytosolic phosphodiesterases in the erythrocyte: a possible role for PDE5. Med Sci Monit. 2011, 17:CR241-7. 10.12659\/msm.881763","journal-title":"Med Sci Monit"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-310746","article-title":"Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction","volume":"103","author":"Andersson DP","year":"2017","unstructured":"Andersson DP, Trolle Lagerros Y, Grotta A, Bellocco R, Lehtihet M, Holzmann MJ. Association between treatment for erectile dysfunction and death or cardiovascular outcomes after myocardial infarction. Heart. 2017, 103:1264-70. 10.1136\/heartjnl-2016-310746","journal-title":"Heart"},{"key":"ref24","article-title":"PDE5 inhibitors","author":"Dhaliwal A","year":"2023","unstructured":"Dhaliwal A, Gupta M. PDE5 inhibitors. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.pupt.2015.03.002","article-title":"Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: a meta-analysis focusing on 6MWD","volume":"32","author":"He CJ","year":"2015","unstructured":"He CJ, Chen SJ, Wang J, Zhu CY, Yin YH. Efficacy and safety of phosphodiesterase type-5 inhibitors for pulmonary arterial hypertension: a meta-analysis focusing on 6MWD. Pulm Pharmacol Ther. 2015, 32:24-8. 10.1016\/j.pupt.2015.03.002","journal-title":"Pulm Pharmacol Ther"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield MM","year":"2013","unstructured":"Redfield MM, Chen HH, Borlaug BA, et al.. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013, 309:1268-77. 10.1001\/jama.2013.2024","journal-title":"JAMA"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24129971","article-title":"Pulmonary hypertension in left heart diseases: pathophysiology, hemodynamic assessment and therapeutic management","volume":"24","author":"Ltaief Z","year":"2023","unstructured":"Ltaief Z, Yerly P, Liaudet L. Pulmonary hypertension in left heart diseases: pathophysiology, hemodynamic assessment and therapeutic management. Int J Mol Sci. 2023, 24:9971. 10.3390\/ijms24129971","journal-title":"Int J Mol Sci"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-020-01671-2","article-title":"Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study","volume":"20","author":"Belyavskiy E","year":"2020","unstructured":"Belyavskiy E, Ovchinnikov A, Potekhina A, Ageev F, Edelmann F. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study. BMC Cardiovasc Disord. 2020, 20:408. 10.1186\/s12872-020-01671-2","journal-title":"BMC Cardiovasc Disord"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002994","article-title":"Prostacyclin for pulmonary hypertension","author":"Paramothayan NS","year":"2003","unstructured":"Paramothayan NS, Lasserson TJ, Wells AU, Walters EH. Prostacyclin for pulmonary hypertension. Cochrane Database Syst Rev. 2003, CD002994. 10.1002\/14651858.CD002994","journal-title":"Cochrane Database Syst Rev"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210236","article-title":"Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial","volume":"76","author":"Coghlan JG","year":"2017","unstructured":"Coghlan JG, Gali\u00e8 N, Barber\u00e0 JA, et al.. Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Ann Rheum Dis. 2017, 76:1219-27. 10.1136\/annrheumdis-2016-210236","journal-title":"Ann Rheum Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm.2020.02.597","article-title":"Current and emerging therapeutic approaches to pulmonary hypertension","volume":"21","author":"Bisserier M","year":"2020","unstructured":"Bisserier M, Pradhan N, Hadri L. Current and emerging therapeutic approaches to pulmonary hypertension. Rev Cardiovasc Med. 2020, 21:163-79. 10.31083\/j.rcm.2020.02.597","journal-title":"Rev Cardiovasc Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.18502\/jovr.v16i2.9088","article-title":"Phosphodiesterase type 5 inhibitors and visual side effects: a narrative review","volume":"16","author":"Barroso F","year":"2021","unstructured":"Barroso F, Ribeiro JC, Miranda EP. Phosphodiesterase type 5 inhibitors and visual side effects: a narrative review. J Ophthalmic Vis Res. 2021, 16:248-59. 10.18502\/jovr.v16i2.9088","journal-title":"J Ophthalmic Vis Res"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002037","article-title":"Phosphodiesterase type 5 inhibitors and risk of malignant melanoma: matched cohort study using primary care data from the UK clinical practice research datalink","volume":"13","author":"Matthews A","year":"2016","unstructured":"Matthews A, Langan SM, Douglas IJ, Smeeth L, Bhaskaran K. Phosphodiesterase type 5 inhibitors and risk of malignant melanoma: matched cohort study using primary care data from the UK clinical practice research datalink. PLoS Med. 2016, 13:e1002037. 10.1371\/journal.pmed.1002037","journal-title":"PLoS Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1007\/s11897-023-00632-y","article-title":"Heart failure and erectile dysfunction: a review of the current evidence and clinical implications","volume":"20","author":"Carella MC","year":"2023","unstructured":"Carella MC, Forleo C, Stanca A, et al.. Heart failure and erectile dysfunction: a review of the current evidence and clinical implications. Curr Heart Fail Rep. 2023, 20:530-41. 10.1007\/s11897-023-00632-y","journal-title":"Curr Heart Fail Rep"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1177\/2045893217719250","article-title":"Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension","volume":"7","author":"Kingman M","year":"2017","unstructured":"Kingman M, Archer-Chicko C, Bartlett M, Beckmann J, Hohsfield R, Lombardi S. Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulm Circ. 2017, 7:598-608. 10.1177\/2045893217719250","journal-title":"Pulm Circ"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2019-0037","article-title":"Comparative effectiveness of pulmonary arterial hypertension drugs in treatment-naive patients: a network meta-analysis","volume":"9","author":"Petrovi\u010d M","year":"2020","unstructured":"Petrovi\u010d M, Locatelli I. Comparative effectiveness of pulmonary arterial hypertension drugs in treatment-naive patients: a network meta-analysis. J Comp Eff Res. 2020, 9:7-22. 10.2217\/cer-2019-0037","journal-title":"J Comp Eff Res"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"61","author":"Humbert M","year":"2023","unstructured":"Humbert M, Kovacs G, Hoeper MM, et al.. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023, 61:10.1183\/13993003.00879-2022","journal-title":"Eur Respir J"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12304","article-title":"Differential drug response in pulmonary arterial hypertension: the potential for precision medicine","volume":"13","author":"Miller E","year":"2023","unstructured":"Miller E, Sampson CU, Desai AA, Karnes JH. Differential drug response in pulmonary arterial hypertension: the potential for precision medicine. Pulm Circ. 2023, 13:e12304. 10.1002\/pul2.12304","journal-title":"Pulm Circ"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2022.101236","article-title":"Recent advances and future prospects of treatment of pulmonary hypertension","volume":"48","author":"Hajra A","year":"2023","unstructured":"Hajra A, Safiriyu I, Balasubramanian P, et al.. Recent advances and future prospects of treatment of pulmonary hypertension. Curr Probl Cardiol. 2023, 48:101236. 10.1016\/j.cpcardiol.2022.101236","journal-title":"Curr Probl Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/401615-the-role-of-phosphodiesterase-5-enzyme-inhibitors-and-prostacyclin-analogs-in-reactive-pulmonary-vasculopathy-in-systolic-heart-failure-a-narrative-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T13:52:59Z","timestamp":1757080379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/401615-the-role-of-phosphodiesterase-5-enzyme-inhibitors-and-prostacyclin-analogs-in-reactive-pulmonary-vasculopathy-in-systolic-heart-failure-a-narrative-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":39,"URL":"https:\/\/doi.org\/10.7759\/cureus.91665","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,9,5]]}}}